U.S. markets closed

Cerecor Inc. (CERC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.6700+0.1500 (+4.26%)
At close: 4:00PM EDT

Cerecor Inc.

540 Gaither Road
Suite 400
Rockville, MD 20850
United States
410 522 8707

Full Time Employees30

Key Executives

NameTitlePayExercisedYear Born
Mr. Michael F. ColaCEO, Pres & Director464.99kN/A1960
Dr. Garry A. NeilChief Scientific Officer705.48kN/A1954
Dr. H. Jeffery Wilkins M.D.Chief Medical Officer547.42kN/A1962
Dr. Solomon H. SnyderFounder and Chairman of Scientific Advisory BoardN/AN/A1939
Dr. Barbara S. SlusherFounder and Member of Scientific Advisory BoardN/AN/A1965
Mr. Schond L. GreenwayCFO, Principal Financial Officer & TreasurerN/AN/A1972
Mr. Christopher Ryan SullivanChief Accounting Officer & Principal Accounting OfficerN/AN/A1984
Dr. Lisa HeggVP of R&D Programs and Project ManagementN/AN/AN/A
Dr. Younok Dumortier Shin M.B.A., Ph.D.Chief Technology OfficerN/AN/AN/A
Mr. James Archie Harrell Jr.Chief Commercial OfficerN/AN/A1970
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Cerecor Inc., a biopharmaceutical company, focuses on development and commercialization of treatments for rare and orphan diseases. The company develops monosaccharide therapies for the treatment of congenital disorders of glycosylation, such as CERC-801, CERC-802, and CERC-803. It is also involved in the developing of CERC-007, an anti-IL-18 monoclonal antibody for the treatment of adult onset stills disease and multiple myeloma, as well as for the treatment of systemic juvenile idiopathic arthritis; CERC-006, an oral mTORC1/2 inhibitor to treat complex lymphatic malformations; and CERC-002, an anti-LIGHT monoclonal antibody that is in phase 2 clinical trial for the treatment of COVID-19 acute respiratory distress syndrome, as well as for the treatment of pediatric-onset Crohn's diseases. In addition, the company offers Millipred, an oral prednisolone for the treatment of inflammatory conditions, such as arthritis, blood disorders, immune system disorders, skin and eye conditions, respiratory disorders, cancer, and severe allergies. Cerecor Inc. has a collaboration agreement with The Frontiers in Congenital Disorders of Glycosylation Consortium on pivotal trial of CERC-801 for the treatment of Phosphoglucomutase-1 deficiency related congenital disorders of glycosylation. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Corporate Governance

Cerecor Inc.’s ISS Governance QualityScore as of June 1, 2021 is 8. The pillar scores are Audit: 10; Board: 5; Shareholder Rights: 6; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.